

Which Patients Are Appropriate Candidates for the Epitomee® Capsule?

- Epitomee® is indicated for weight management in overweight adults with a BMI of 25-40 kg/m², when used in conjunction with diet and physical activity.
See further detailed information in the Epitomee® Capsule instruction of use including contraindications and precautions sections.
- Individuals who want a non-drug, non-surgical approach.
- Individuals who experienced GLP-1 intolerance.
- Individuals seeking other weight management options after completing medication-based interventions.
- Individuals who struggle with portion control or early satiety and have had little success with diet and exercise.
- Individuals without comorbidities who don't qualify for GLP-1 medications. It fills the gap for lower-BMI patients underserved by current treatments.



Mechanism of Action

Each Epitomee® Capsule contains a proprietary polymer formulation that expands in the stomach once ingested with water to form a semi-rigid, triangle shape structure.

This structure mimics the sensation of fullness and triggers the vagus nerve, helping patients reduce portion size and eat less without feeling deprived.



INGESTING

Swallow one capsule with two 8-ounce (250 ml) glasses of water 30 minutes before lunch and dinner.



EXPANDING

Once in your stomach, the device inside the capsule absorbs the water and gently expands into a triangle shape.



SATIATING

The expanded triangle gently presses on your stomach walls, signaling fullness to your brain.



DISINTEGRATING

After several hours, the capsule breaks down completely in the small intestine and is naturally cleared out of the body.

*Refers to the device's mechanism of action.

Simple to Integrate Into Your Practice

- 1 Dosing:** Take one capsule, twice daily, with two cups of water (8 ounces or 250 ml), 30 minutes before lunch and dinner.
- 2 Program:** The Epitomee® treatment is indicated for use alongside diet and physical activity.
- 3 Monitoring:** Routine follow-up to support behavior change and track progress.
- 4 Prescribed through select providers or specialty pharmacies.**



EASE OF USE

“Patients consistently reported that the Epitomee® treatment was simple to incorporate into their daily routine with exceptional adherence, demonstrating that Epitomee® Capsule use is also convenient and easy to maintain.”



Donna Ryan, MD
Professor Emerita at Pennington Biomedical Research Center

Scan for Website



epitomee®
weight management capsule

The *Brilliant* Little Weight Management Capsule



Contact Us

(000) 000 000
contact@Epitomeecapsule.com
Epitomeecapsule.com

Epitomee® Capsule, FDA cleared, Rx Only, is indicated to aid weight management in adults with excess weight or obesity, Body Mass Index (BMI) of 25-40 kg/m², when used in conjunction with diet and exercise. Epitomee® is contraindicated for use during pregnancy and in individuals with a known history of allergic reactions to any of its components. Please read the patient information leaflet before use. For more information, please visit our website at epitomeecapsule.com. Manufacturer: Epitomee Medical, 17 Hatochen St. Caesarea 3079892, Israel.

1 Jakicic JM, Ryan DH, Ard JD, et al. Association of the Early Response to an Oral Shape-Shifting Superabsorbent Hydrogel Capsule with Weight Loss. Clin Obes. 2025; In Review. 2 Kamar M, Ryan DH, Leonard S, et al. The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: the ELECT extension study. Obesity Science and Practice. 2025; In Review. 3 Ard JD, Ryan DH, O'Neil PM, et al. Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study. Obesity. 2025 4 Bays HE, Ard JD, O'Neil PM, et al. Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: Prespecified and exploratory analysis of the Epitomee capsule RESET Study. Obes Pillars. 2025. 5 Kushner RF, Ard JD, Wadden TA, et al. Quality of Life Improvements Associated with Weight Loss Using a Novel Shape-Shifting Hydrogel Capsule: RESET Study Results. International Journal of Obesity. 2025; In Review.

epitomee®
weight management capsule



A Groundbreaking Innovation in *Non-Drug* Weight Management

Revolutionizing Weight Management Through Science and Technology

The Epitomee® Capsule is a FDA-cleared, drug-free capsule designed to support weight management by promoting satiety through a mechanical, rather than pharmacological approach.

Redefining *Weight Management* with Science and Simplicity

The Epitomee® Capsule offers your patients a manageable, prescription-only solution for achieving and maintaining a healthier weight—without the risks associated with pharmacologic treatments.

For patients who have struggled with portion control, GLP-1 intolerance, or weight rebound, the Epitomee® Capsule offers a science-backed solution to help reduce caloric intake while supporting lifestyle changes.



FDA CLEARED
CLINICALLY PROVEN
DRUG FREE



A Novel Technology

Science-based capsule mimics food with no stimulants, no strict diets—just appetite control for patients success.



Non-Drug Alternative

A clinically proven, safe, non-pharmacological approach to portion control and appetite regulation.



Filling the Treatment Gap

Ideal for patients who aren't ready/eligible for medication or surgery but need more than lifestyle changes alone.



Simplicity & Adherence

It's easy-to-use, supporting adherence without complex routines or behavioral exhaustion.

Evidence-Based Efficacy


Clinical Results for Safe, Long Term Weight Loss

PREDICTABLE WEIGHT LOSS

Early Responders Lost 9.3% of Their Body Weight Over 24 Weeks¹

Early weight loss with Epitomee® treatment (losing at least 2% at week 8) resulted in an average weight loss of 9.3% within 24 weeks.

*** p<0.001 Epitomee® versus placebo early responders




SUSTAINABLE RESULTS

11.2% Body Weight Lost Over 48 Weeks in Ext. Study²

Participants who completed 24 weeks of treatment with Epitomee® and lost at least 3%, joined the extension study for additional of 24 weeks and had lost 11.3% of baseline body weight after 24 weeks. With 24 additional weeks of Epitomee® and lifestyle counseling, these participants maintained a loss of 11.2% of baseline body weight at week 48.

Those on placebo lost 6.0% after 24 weeks. After switching to the Epitomee® Capsule, they lost an additional 1.5% over the next 24 weeks.


p<0.01; *p<0.001



LOW RISK

Zero Related Serious Adverse Events³

The Epitomee® Capsule is designed to provide effective results with a favorable safety profile. Adverse events reported by participants were similar between the Epitomee® and placebo groups, indicating that the Epitomee® treatment has no apparent side effects.




Clinical Results for Improved Health Conditions

IMPROVED METABOLIC SYNDROME

Helps Reduce the Risk of Metabolic Syndrome⁴

Weight Loss with the Epitomee® Capsule can potentially improve glycemic control and other cardiometabolic risk factors, contributing to improved overall health.

Of the 27 participants in the Epitomee® Capsule group with MetS at baseline, 16 (60%) no longer had 3 or more diagnostic components of the MetS at week 24. Among participants with MetS, those taking the Epitomee® Capsule lost significantly more weight than those on placebo. (8.3% vs. 5.2%; p < 0.0004).




IMPROVED INSULIN LEVELS

Helps Reduce the Risk of Diabetes⁴

Weight loss in study participants with prediabetes was associated with significant improvements in insulin levels and insulin resistance (HOMA-IR) within 24 weeks, reducing their risk of developing diabetes compared to those receiving a placebo.

**p<0.01



Clinical Results for Improved Well-Being

IMPROVED OVERALL HEALTH

Experience Measurable Improvement In Quality of Life⁵

Weight loss in both Epitomee® participants and placebo significantly improved their quality of life from baseline (# p < 0.05). However, compared to placebo, the Epitomee® Capsule group exhibited significantly greater improvements in Physical Function and IWQOL-Lite-CT total scores (*p < 0.05).

